Unknown

Dataset Information

0

A review of the pharmacogenomics of buprenorphine for the treatment of opioid use disorder.


ABSTRACT: As the opioid epidemic continues to grow across the United States, the number of patients requiring treatment for opioid use disorder continues to climb. Although medication-assisted treatment presents a highly effective tool that can help address this epidemic, its use has been limited. Nonetheless, with easier dosing protocols (compared to the more complex dosing required of methadone due to its long and variable half-life) and fewer prescribing limitations (may be prescribed outside the setting of federally approved clinics), the increase in buprenorphine use in the United States has been dramatic in recent years. Despite buprenorphine's demonstrated efficacy, patient-specific factors can alter the response to the medications, which may lead to treatment failure in some patients. Clinical characteristics (sex, concurrent medications, and mental health comorbidities) as well as social determinants of health (housing status, involvement with the criminal justice system, and socioeconomic status) may impact treatment outcomes. Furthermore, a growing body of data suggests that genetic variations can alter pharmacological effects and influence therapeutic response. This review will cover the available pharmacogenomic data for the use of buprenorphine in the management of opioid use disorders. Pharmacogenomic determinants that affect opioid receptors, the dopaminergic system, metabolism of buprenorphine, and adverse events are discussed. Although much of the existing data comes from observational studies, clinical research is ongoing. Nevertheless, the development of pharmacogenomic-guided strategies has the potential to reduce opioid misuse, improve clinical outcomes, and save healthcare resources.

SUBMITTER: Segui HA 

PROVIDER: S-EPMC7709797 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature

altmetric image

Publications

A review of the pharmacogenomics of buprenorphine for the treatment of opioid use disorder.

Seguí Hemanuel Arroyo HA   Melin Kyle K   Quiñones Darlene Santiago DS   Duconge Jorge J  

Journal of translational genetics and genomics 20200730


As the opioid epidemic continues to grow across the United States, the number of patients requiring treatment for opioid use disorder continues to climb. Although medication-assisted treatment presents a highly effective tool that can help address this epidemic, its use has been limited. Nonetheless, with easier dosing protocols (compared to the more complex dosing required of methadone due to its long and variable half-life) and fewer prescribing limitations (may be prescribed outside the setti  ...[more]

Similar Datasets

| S-EPMC9549700 | biostudies-literature
| S-EPMC9518754 | biostudies-literature
| S-EPMC7108757 | biostudies-literature
| S-EPMC8397932 | biostudies-literature
| S-EPMC6028283 | biostudies-literature
| S-EPMC7002204 | biostudies-literature
| S-EPMC8186092 | biostudies-literature
| S-EPMC8283555 | biostudies-literature
| S-EPMC9529783 | biostudies-literature
| S-EPMC8384722 | biostudies-literature